# Epigenomics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/epigenomics

- Industry: Medical Devices & Equipment
- Headquarters: Berlin, Germany
- Website: www.epigenomics.com
- Total disclosed funding: $48M
- Latest round: Series C (Apr 3, 2003)
- Investors on record: 6

## About

Epigenomics AG is a biotechnology company focused on developing minimally invasive blood tests for cancer detection, primarily targeting colorectal cancer through innovative epigenetic biomarkers.Founded in 1998 and headquartered in Berlin, Germany, Epigenomics AG specializes in cancer diagnostics. The company completed a successful PIPE funding round in July 2004, raising EUR 33.10 mn, and has engaged in a total of 6 deals. The current CEO is Noel Doheny.Epigenomics AG specializes in the development and commercialization of minimally invasive blood tests for cancer detection. Their core product, the Epi proColon test, detects methylated Septin9 DNA in blood samples, offering a non-invasive alternative to traditional colonoscopy. Their products are aimed at healthcare providers, hospitals, and laboratories across various markets, including Germany and the United States, facilitating early cancer detection for diverse client needs.In 2023, Epigenomics AG reported a revenue of EUR 367,178.60, with an EBITDA of EUR -4,791,935.80. The company’s revenue model hinges on sales of its diagnostic tests to healthcare providers and laboratories, reflecting the importance of its flagship Epi proColon test in their financial performance.Epigenomics AG plans to leverage its recent funding to expand its product offerings and market reach. The funds will support the development of new diagnostic products targeting various cancer types and enhance distribution capabilities in existing markets. The company aims to broaden its geographic presence in Europe and the United States, with specific plans to enter new regions by the end of 2024. This growth strategy is supported by the funds raised during its PIPE funding round.

## Funding rounds

- Series C, Apr 3, 2003, $23M — 3i, Abingworth, Wellcome Trust, KfW Banking Group, MPM BioImpact, Deutsch Venture Capital Gessellschaft
- Series B, Nov 14, 2000, $25M — 3i, Abingworth, MPM BioImpact, Deutsch Venture Capital Gessellschaft

## Investors

- 3i (https://capitalatlas.ai/funds/3i) — Series B, Series C
- Abingworth (https://capitalatlas.ai/funds/abingworth) — Series B, Series C
- MPM BioImpact (https://capitalatlas.ai/funds/mpm-bioimpact) — Series B, Series C
- Deutsch Venture Capital Gessellschaft — Series B, Series C
- Wellcome Trust — Series C
- KfW Banking Group — Series C